Purpose: This systematic review and meta-analysis compared the diagnostic performance of MRI, [18F]FDG-PET/CT, and [18F]FDG-PET/MRI in detecting focal bone lesions and bone marrow infiltration in the initial staging of patients with multiple myeloma (MM) who underwent both MRI and [18F]FDG-PET/CT or [18F]FDG-PET/MRI studies. Patients and Methods: A systematic literature search was conducted across PubMed, Embase, and Cochrane databases, including studies comparing the performance of MRI (WB-MRI or spine/pelvis MRI), [18F]FDG-PET/CT, and/or [18F]FDG-PET/MRI in the same patients for MM initial staging. Pooled sensitivities and concordance between imaging modalities were analyzed using R (package META-R). Heterogeneity and bias were assessed with the QUADAS-C tool. Results: Twenty studies (published between 2007 and 2025) using the international MM diagnostic criteria as a reference standard met the inclusion criteria. Of these, 13 (n=742) compared per-patient sensitivity of [18F]FDG-PET/CT and MRI, and 4 (n=224) compared MRI and [18F]FDG-PET/MRI. Pooled sensitivities were 0.807 (95% CI: 0.74–0.86) for [18F]FDG-PET/CT (with significant heterogeneity) versus 0.914 (95% CI: 0.88–0.94) for MRI (0.906 for spine/pelvis MRI and 0.920 for WB-MRI) (P<0.001 for meta-regression analysis). Using contingency tables, 83% (599/721) of included patients had concordant [18F]FDG-PET/CT and MRI results, while 14% (101/721) patients had negative [18F]FDG-PET/CT and positive MRI with significant differences between the 2 techniques for the paired sample analysis (P<0.001). The pooled sensitivity of the 4 studies including [18F]FDG-PET/MRI was 0.944 (95% CI: 0.88–0.98). Consensus definitions for specificity in MM imaging should be standardized across studies. Conclusions: This systematic review and comparative meta-analysis demonstrates superior sensitivity of WB-MRI compared with [18F]FDG-PET/CT for initial staging of MM patients. Future international guidelines might prioritize MRI and [18F]FDG-PET/MRI for staging of MM patients. Registration: PROSPERO CRD42024564937.
21 August 2025 in Physics and Imaging in Radiation Oncology
Predicting hepatocellular carcinoma (HCC) response to Stereotactic Body Radiation Therapy (SBRT) can be challenging. Here, we assessed the value of a radiomics-based machine learning (ML) approach for predicting HCC response to SBRT, using pre-treatment and early post-treatment magnetic resonance imaging (MRI). This retrospective single-center study included 87 patients (M 67, mean age 65.3 ± 9.1y) with HCC treated with SBRT who underwent gadoxetate MRI both pre- and early post-treatment (around 9.5 weeks). Tumor radiomics features were extracted on pre- and post-SBRT MRIs on pre- and post-contrast T1-weighted imaging (T1WI) [pre-contrast, arterial phase (AP), portal venous phase (PVP), transitional phase and hepatobiliary phase]. Long term response was assessed using modified RECIST criteria. Different ML models were developed based on 1st and 2nd order radiomics features to predict long-term objective response (partial and complete response) versus no response (stable and progressive disease). The cohort was randomly divided into training/validation (70 %) and testing 30 %. A total of 87 tumors were assessed (mean size 2.7 ± 1.6 cm). Objective long-term response was observed in 43 (49.4 %) patients. The best predictive outcomes were achieved using models combining pre- and early post-treatment radiomics, with top performing model combining pre-treatment T1WI-pre-contrast, pre-treatment T1WI-AP and post-treatment T1WI-PVP, achieving an AUC of 0.85 [95 % CI: 0.67–––1], sensitivity of 0.7 and specificity of 1. Our initial findings show promising results for ML radiomics in predicting long-term response of HCC to SBRT, which may have implications for management decisions.